180 related articles for article (PubMed ID: 35414773)
1. IKZF1 selectively enhances homologous recombination repair by interacting with CtIP and USP7 in multiple myeloma.
Liu M; Zhang Y; Wu Y; Jin J; Cao Y; Fang Z; Geng L; Yang L; Yu M; Bu Z; Ji Y; Shan H; Zou Z; Liu L; Wang Y; Zhang Y; Tong Y; Xu H; Lei H; Liu W; Gao F; Wu Y
Int J Biol Sci; 2022; 18(6):2515-2526. PubMed ID: 35414773
[No Abstract] [Full Text] [Related]
2. Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma.
Morra F; Merolla F; D'Abbiero D; Ilardi G; Campione S; Monaco R; Guggino G; Ambrosio F; Staibano S; Cerrato A; Visconti R; Celetti A
Lung Cancer; 2019 Sep; 135():56-65. PubMed ID: 31447003
[TBL] [Abstract][Full Text] [Related]
3. UBE2O and USP7 co-regulate RECQL4 ubiquitinylation and homologous recombination-mediated DNA repair.
Huang Q; Qin D; Pei D; Vermeulen M; Zhang X
FASEB J; 2022 Jan; 36(1):e22112. PubMed ID: 34921745
[TBL] [Abstract][Full Text] [Related]
4. CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer.
Morra F; Merolla F; Criscuolo D; Insabato L; Giannella R; Ilardi G; Cerrato A; Visconti R; Staibano S; Celetti A
J Exp Clin Cancer Res; 2019 Feb; 38(1):90. PubMed ID: 30786932
[TBL] [Abstract][Full Text] [Related]
5. Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors.
Cheng X; Zhang B; Guo F; Wu H; Jin X
Mol Oncol; 2022 Apr; 16(7):1591-1607. PubMed ID: 34854226
[TBL] [Abstract][Full Text] [Related]
6. USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.
Malapelle U; Morra F; Ilardi G; Visconti R; Merolla F; Cerrato A; Napolitano V; Monaco R; Guggino G; Monaco G; Staibano S; Troncone G; Celetti A
Lung Cancer; 2017 May; 107():41-49. PubMed ID: 27372520
[TBL] [Abstract][Full Text] [Related]
7. The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells.
Morra F; Merolla F; Napolitano V; Ilardi G; Miro C; Paladino S; Staibano S; Cerrato A; Celetti A
Oncotarget; 2017 May; 8(19):31815-31829. PubMed ID: 28415632
[TBL] [Abstract][Full Text] [Related]
8. c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma.
Osada N; Kikuchi J; Iha H; Yasui H; Ikeda S; Takahashi N; Furukawa Y
Clin Transl Med; 2023 Aug; 13(8):e1364. PubMed ID: 37581569
[TBL] [Abstract][Full Text] [Related]
9. USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.
Agathanggelou A; Smith E; Davies NJ; Kwok M; Zlatanou A; Oldreive CE; Mao J; Da Costa D; Yadollahi S; Perry T; Kearns P; Skowronska A; Yates E; Parry H; Hillmen P; Reverdy C; Delansorne R; Paneesha S; Pratt G; Moss P; Taylor AMR; Stewart GS; Stankovic T
Blood; 2017 Jul; 130(2):156-166. PubMed ID: 28495793
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitin-specific protease 7 regulates nucleotide excision repair through deubiquitinating XPC protein and preventing XPC protein from undergoing ultraviolet light-induced and VCP/p97 protein-regulated proteolysis.
He J; Zhu Q; Wani G; Sharma N; Han C; Qian J; Pentz K; Wang QE; Wani AA
J Biol Chem; 2014 Sep; 289(39):27278-27289. PubMed ID: 25118285
[TBL] [Abstract][Full Text] [Related]
11. USP7-mediated deubiquitination differentially regulates CSB but not UVSSA upon UV radiation-induced DNA damage.
Zhu Q; Ding N; Wei S; Li P; Wani G; He J; Wani AA
Cell Cycle; 2020 Jan; 19(1):124-141. PubMed ID: 31775559
[TBL] [Abstract][Full Text] [Related]
12. Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Zheng J; Sha Y; Roof L; Foreman O; Lazarchick J; Venkta JK; Kozlowski C; Gasparetto C; Chao N; Ebens A; Hu J; Kang Y
Cancer Lett; 2019 Jan; 440-441():1-10. PubMed ID: 30312729
[TBL] [Abstract][Full Text] [Related]
13. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Krönke J; Kuchenbauer F; Kull M; Teleanu V; Bullinger L; Bunjes D; Greiner A; Kolmus S; Köpff S; Schreder M; Mügge LO; Straka C; Engelhardt M; Döhner H; Einsele H; Bassermann F; Bargou R; Knop S; Langer C
Leukemia; 2017 Jun; 31(6):1363-1367. PubMed ID: 28017969
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.
Krönke J; Udeshi ND; Narla A; Grauman P; Hurst SN; McConkey M; Svinkina T; Heckl D; Comer E; Li X; Ciarlo C; Hartman E; Munshi N; Schenone M; Schreiber SL; Carr SA; Ebert BL
Science; 2014 Jan; 343(6168):301-5. PubMed ID: 24292625
[TBL] [Abstract][Full Text] [Related]
15. The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival.
He Y; Wang S; Tong J; Jiang S; Yang Y; Zhang Z; Xu Y; Zeng Y; Cao B; Moran MF; Mao X
J Biol Chem; 2020 Feb; 295(7):2084-2096. PubMed ID: 31822558
[TBL] [Abstract][Full Text] [Related]
16. Dual-utility NLS drives RNF169-dependent DNA damage responses.
An L; Jiang Y; Ng HH; Man EP; Chen J; Khoo US; Gong Q; Huen MS
Proc Natl Acad Sci U S A; 2017 Apr; 114(14):E2872-E2881. PubMed ID: 28325877
[TBL] [Abstract][Full Text] [Related]
17. Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.
Wang J; Ding Q; Fujimori H; Motegi A; Miki Y; Masutani M
Oncotarget; 2016 Feb; 7(7):7701-14. PubMed ID: 26713604
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies.
Gaymes TJ; Mohamedali AM; Patterson M; Matto N; Smith A; Kulasekararaj A; Chelliah R; Curtin N; Farzaneh F; Shall S; Mufti GJ
Haematologica; 2013 Sep; 98(9):1397-406. PubMed ID: 23349304
[TBL] [Abstract][Full Text] [Related]
19. Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.
Kari V; Mansour WY; Raul SK; Baumgart SJ; Mund A; Grade M; Sirma H; Simon R; Will H; Dobbelstein M; Dikomey E; Johnsen SA
EMBO Rep; 2016 Nov; 17(11):1609-1623. PubMed ID: 27596623
[TBL] [Abstract][Full Text] [Related]
20. A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.
Alagpulinsa DA; Ayyadevara S; Yaccoby S; Shmookler Reis RJ
Mol Cancer Ther; 2016 Feb; 15(2):241-50. PubMed ID: 26719576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
